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ABSTRACT 
Objective: Objective of the present study was to develop an immediate release solid dispersion tablet to enhance oral bioavailability of Azilsartan.  
Methods: Solid dispersion of azilsartan was developed using Soluplus® as a novel solubility enhancer by the solvent evaporation technique. 
32
Results: Results of micromeritic properties of solid dispersion showed that good flowability, compressibility, wettability, and saturation solubility. 
Post compression parameters of immediate-release tablets were found to be in acceptable limits. Batch ASD2 containing 40 mg Diacerein and 80 mg 
of Soluplus showed maximum drug release i.e. 99.82 % within 30 min. Compatibility study using FTIR, DSC, and XRD showed that drug is 
compatible with Soluplus. In vivo absorption study showed that, 2.67 fold increase in Area Under Curve (AUC) as compared to plain Azilsartan. 
Relative bioavailability was found to be 267.11 %. Results of stability study indicate that developed formulations were stable at accelerated 
temperature and humidity conditions.  
factorial design was used in a fully randomized order to study effect of amount of azilsartan and Soluplus on solubility (µg/ml) and % drug 
dissolved in 30 min. Prepared solid dispersion was evaluated for different micromeritic properties, saturation solubility, and wettability. Then solid 
dispersion of all the batches compressed into an immediate-release tablet using sodium starch glycolate as a super disintegrant. Developed tablet 
formulations were evaluated for various post-compression parameters and satisfactory formulation among these were further studied for Fourier-
transform infrared spectroscopy (FTIR), Differential Scanning Colorimeter (DSC), X-Ray Diffraction (XRD), in vivo absorption and stability study.  
Conclusion: Study concluded that solid dispersion using Soluplus as a solubility enhancer is a suitable formulation strategy to enhance solubility, 
dissolution, and bioavailability of poorly water-soluble drug-like Azilsartan. 
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INTRODUCTION 
Solid dispersion is dispersion of one or more active ingredients in an 
inert carrier at solid-state prepared by fusion, solvent or solvent fusion 
method [1]. The solvent evaporation method is one of the most 
commonly used methods in the pharmaceutical industry for 
improving solubility of poorly water-soluble drugs [2]. This method 
was developed mainly for heat unstable components because drug and 
carrier are mixed by a solvent instead of heat as in the melting method. 
Therefore, this method allows use of carriers with an excessively high 
melting point [3]. Soluplus® is Polyvinyl caprolactam–polyvinyl 
acetate–polyethylene glycol graft copolymer with amphiphilic 
properties, designed and developed for solid solutions. Unlike classical 
solubilizers, its bifunctional character can be considered as a member 
of the fourth generation of solid dispersions [4]. 
 
 
Fig. 1: Chemical structure of azilsartan [7, 8] 
 
Azilsartan is a selective AT1subtype angiotensin II receptor antagonist 
which is one of the widely used antihypertensive drug. It lowers blood 
pressure by blocking the action of angiotensin II at the AT1 receptor, a 
hormone that contracts blood vessels and reduces water excretion 
through the kidneys [5]. Azilsartan was discovered in 2011. But to 
date, it is used in form of prodrug (in salt form) azilsartan medoxomil 
which has been approved in both the United state and Europe. In 
2012, the parent compound azilsartan was approved in Japan for the 
treatment of hypertension. But it has solubility problem which leads to 
low bioavailability, hence it is necessary to improve the solubility of 
Azilsartan [6-8]. Hence study was aimed to develop immediate release 
solid dispersion tablet of Azilsartan to enhance solubility, dissolution 
and hence bioavailability.  
MATERIALS AND METHODS 
Materials 
Azilsartan was obtained from DRVL Mumbai, India as a gift sample. 
Soluplus® was procured from BASF Mumbai Sodium Starch 
Glycolate was obtained from Loba Chemie Pvt. Ltd., Mumbai. All 
other chemicals used were of analytical grade. 
Methods 
Formulation of azilsartan solid dispersion 
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To study all the possible combinations, 3
Factorial design 
2factorial design was 
constructed and conducted in a fully randomized order. Solubility 
(µg/ml) and % drug dissolved in 30 min were selected as dependent 
variables and studied at three different levels of the selected 
independent variables (factors). Details of the selected independent 
variables of the 32
Preparation of solid dispersion  
 factorial design are shown in table 1. Amount of 
Azilsartan taken in three different concentrations viz. 35, 40 and 45 
mg and the amount of soluplus was taken in three different 
concentrations of 40, 60 and 80 mg. The range of a factor was chosen 
to adequately measure its effect on the response variables [9].  
Nine batches (ASD-1 to ASD-9) of solid dispersions of Azilsartan-
Soluplus were prepared by the solvent evaporation method. Briefly, 
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Soluplus was dissolved in methanol under stirring and sonicated until 
a clear solution was obtained. Azilsartan was added with stirring for 
45 min. The solvent was evaporated at 50 °C in an oven until the 
complete drying of samples. The dispersions were then pulverized 
using a mortar and pestle, passed through 60-mesh sieve (250 µm) 
and stored in a desiccator until use for further studies [10, 11]. 
Evaluation of azilsartan solid dispersion  
Micromeritic properties 
Micromeritic properties of solid dispersion; like angle of repose, 
bulk density, tapped density, Carr’s index, and Hausner’s ratio was 
studies as per standard procedures [12, 13]. 
Saturation solubility 
The saturation solubility of solid dispersion batches was determined 
by adding an excess amount of samples to 10 ml of water and 
samples were shaken on an orbital shaker (Remi Instruments Ltd. 
Mumbai) for 72 h at 37 °C. Samples were further centrifuged at 7000 
rpm for 10 min and the supernatant was filtered through a 0.45 
micron membrane filter, suitably diluted and analyzed using a UV–
visible spectrophotometer at 249 nm [14]. 
Wettability study 
Drug powder and solid dispersion (3g) were placed in a sintered 
glass funnel (33 mm i.d.). The funnel was plunged into beaker 
containing water such that the surface of water in the beaker 
remains at the same level as the powder in the funnel. Methylene 
blue powder (100 mg) was layered uniformly on the surface of the 
powder in the funnel. The time required for wetting methylene blue 
powder was measured [15]. 
Formulation of azilsartan solid dispersion immediate release 
tablet 
Azilsartan solid dispersion powder equivalent to 40 mg of Azilsartan 
was blended with 4% super disintegrant such as sodium starch 
glycolate for 2 min. 0.5 % magnesium stearate was added as a 
lubricant and a powder blend of 180 mg (including weight of lactose 
as a diluent) was directly compressed in to tablet using KBr press 
[16, 17]. 
Evaluation of azilsartan solid dispersion immediate release 
tablet 
The tablets were evaluated for the following post-compression 
parameters [18-20]. 
Hardness 
Five tablets were randomly selected and tested for their hardness. 
Tablet was placed diametrically between the holding anvil and the 
piston connected to the direct force reading gauge of tester 
(Monsanto tester). Force was applied to the anvil and the crushing 
strength that just causes the tablet to break was recorded. 
Thickness 
Thickness of tablet is important for uniformity of tablet size. 
Thickness was measured using Vernier Calipers (Mitutoyo 
Corporation India). It was determined by checking ten tablets from 
each formulation. 
Friability 
Pre-weighed tablets (n=10) were placed in Roche friabilator which 
was then operated for 100 revolutions (25 rpm, 4 min). The tablets 
were then dusted and reweighed to check the loss in its weight. The 
friability (%) was calculated using the following equation. 
Friability(%) =




The average weight of 20 tablets was determined by individually 
weighing the tablets. By comparing the individual weights to the 
average weight, tablet weight variation was determined. 
Drug content 
Ten tablets (180 mg) were powdered in a mortar pestle and the 
blend equivalent to 1 mg of Azilsartan was weighed and dissolved in 
the 10 ml volumetric flask. To this sufficient quantity of methanol 
was added and the flask was shaken for 10 min. Then the volume 
was made with methanol. This was then filtered through nylon filter 
paper (0.45 µm), and from filtrate exactly 1 ml was transferred to 
another volumetric flask of 10 ml and volume was made with 
methanol. The UV absorbance of this was taken at 249 nm [21]. 
Disintegration test 
One tablet is placed in each tube of disintegration test apparatus and 
the basket rack is poisoned in 1 liter beaker of distilled water at 
37±2 °C, such that the tablets remain below the surface of the liquid 
on their upward movement and descend not closer than 2.5 cm from 
the bottom of the beaker. 
In vitro dissolution study 
In vitro dissolution study was carried out in the United States 
Pharmacopeia (USP) Type-II dissolution test apparatus. The 
dissolution medium used was 900 ml of phosphate buffer pH 7.8 
maintained at 37.5±0.5 °C. The paddle speed was kept constant at 
100 rpm. Samples of 5 ml were withdrawn at specific time interval 
of 5 min. The withdrawn samples were analyzed by UV spectroscopy 
at the wavelength maxima of 249. The same amount of fresh 
phosphate buffer pH 7.8 was used to replace at each time as amount 
is withdrawn for respective dissolution media [22]. 
Selection and evaluation of satisfactory formulations for 
further study 
Satisfactory formulation of Azilsartan solid dispersion immediate-
release tablet was selected based on the solubility of solid dispersion 
and % drug dissolution after 30 min. Selected formulations were 
further studied for FTIR, DSC, XRD, [23, 24] in vivo absorption and 
stability study. 
In vivo absorption studies in albino rats 
The in vivo absorption studies for pure Azilsartan and optimized 
formulation of ASD2 were carried out using adult albino rats (200-
250 g) received from animal house of Rajarambapu College of 
Pharmacy, Kasegaon. The study was protocol approved by the 
Institutional Animal Ethical Committee of Rajarambapu College of 
Pharmacy, Kasegaon (1290/PO/Re/S/09/CPCSEA). Rats were 
divided into three groups which were control, standard and test 
formulation groups. The animals were kept on standard 
supplemented diet and water for two weeks before the experiment 
and maintained on it thereafter. Tablets with a dose of 5 mg/kg 
body weight of rats were administered by dispersing in distilled 
water through oral feeding pipe. Blood samples were collected 
through the lateral tail vein of rats at 15, 30, 45, 60, 75, 90 min 
after dosing. The blood samples were centrifuged at 7000 rpm for 
10 min and stored at −20  °C until analysis. The plasma 
concentration of the drug was determined by high-performance 
liquid chromatography (HPLC) [8, 25]. 
Accelerated stability study 
Stability study was evaluated according to the ICH guidelines (2003) 
on the topic of Q1A (R2): stability testing of new drug substances 
and products. The optimized formulation of ASD2 was packed in 
polyethylene laminated aluminum foils. Samples maintained in a 
stability chamber under intermediate conditions and evaluated 
under accelerated conditions (45 ⁰C±2 ⁰C, 75±5% RH) with humidity 
and temperature control, were taken at 0, 1, 2 and, 3 mo for both the 
conditions. Drug content and % drug released after 30 min were 
evaluated for the stability study. 
RESULTS AND DISCUSSION 
Formulation of azilsartan solid dispersion 
The full mathematical equation for solubility can be given as:  
Y1 = +87.38−  0.1183XA + 11.46XB 
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Both the Azilsartan and soluplus significantly influenced the 
solubility. The positive coefficient of the concentration of Azilsartan 
and soluplus indicate that solubility increased with an increase in 
the concentration of Azilsartan and soluplus. 
The full mathematical equation for % dissolution can be given as:  
Y2 =  87.01 + 1.20A + 10.23B− 0.4525AB 
Azilsartan and soluplus significantly influenced the percent 
dissolution. The negative coefficient of the concentration of 
Azilsartan and positive coefficient of soluplus indicate that 
dissolution increased with an increase in the concentration soluplus 
and decreased with Azilsartan concentration. 
 
Table 1: Composition of 32
Batch code 
 factorial design batches and responses 
  Factor 1 Factor 2 Response 1 Response 2 
Std Run A: Drug B: Polymer Solubility (µg/ml) % Dissolution 
ASD-1 3 1 45 40 78.39 76.48 
ASD-2 8 2 40 80 87.49 86.79 
ASD-3 4 3 35 60 98.96 98.48 
ASD-4 1 4 35 40 86.42 87.68 
ASD-5 6 5 45 60 76.81 78.23 
ASD-6 9 6 45 80 74.32 79.49 
ASD-7 2 7 40 40 84.76 84.72 
ASD-8 7 8 35 80 102.03 99.82 
ASD-9 5 9 40 60 97.26 97.28 
 
The full mathematical equation for solubility can be given as:  
Y1 = +87.38−  0.1183XA + 11.46XB 
Both the Azilsartan and soluplus significantly influenced the 
solubility. The positive coefficient of the concentration of Azilsartan 
and soluplus indicate that solubility increased with an increase in 
the concentration of Azilsartan and soluplus. 
The full mathematical equation for % dissolution can be given as:  
Y2 =  87.01 + 1.20A + 10.23B− 0.4525AB 
Azilsartan and soluplus significantly influenced the percent 
dissolution. The negative coefficient of the concentration of 
Azilsartan and positive coefficient of soluplus indicate that 
dissolution increased with an increase in the concentration soluplus 
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Fig. 2: (A) and (B): Counter plot and response surface plot showing the effect of variables on solubility respectively, (C) and (D): Counter 
plot and response surface plot showing the effect of variables on % dissolution respectively 
 
Table 2: Micromeritic properties and drug content of azilsartan solid dispersion 
Formulation Angle of 
repose 












ASD-1 31.6±1.32 0.815±0.021 0.985±0.021 17.26±1.02 1.21±0.05 40.6±1.6 74.32±2.63 
ASD-2 25.8±1.21 0.731±0.032 0.835±0.015 12.46±1.06 1.14±0.02 20.2±2.2 102.03±3.48 
ASD-3 29.5±2.32 0.854±0.052 0.987±0.066 13.48±1.04 1.16±0.07 30.4±1.4 84.76±2.66 
ASD-4 29.6±2.14 0.726±0.017 0.941±0.025 22.85±1.05 1.30±0.03 32.5±2.7 78.39±314 
ASD-5 28.2±1.89 0.801±0.029 0.984±0.048 18.60±1.21 1.23±0.08 29.4±1.6 86.42±3.69 
ASD-6 26.3±1.22 0.748±0.058 0.856±0.069 12.62±1.07 1.14±0.04 22.6±1.8 98.96±2.84 
ASD-7 30.1±1.54 0.723±0.048 0.965±0.047 25.08±1.11 1.33±0.06 35.3±2.5 76.81±2.97 
ASD-8 26.4±2.01 0.763±0.034 0.914±0.066 16.52±1.09 1.20±0.08 25.4±1.4 97.26±3.01 
ASD-9 27.3±1.22 0.7±0.088 0.89±0.052 21.35±1.08 1.27±0.07 27.5±2.3 87.49±3.88 
All value represents mean±SD (n=3) 
 
Evaluation of azilsartan solid dispersion 
Results of micromeritic properties, saturation solubility, and 
wettability study are shown in table 2. Solid dispersion batch ASD-2 
containing 40 mg of Azilsartan and 80 mg of soluplus showed good 
flowability, compressibility, wettability, and solubility. 
Results of saturation solubility indicate that as the concentration of 
soluplus increases it decrease wettability time and increase aqueous 
solubility [26]. 
Formulation and evaluation of azilsartan solid dispersion tablet 
All batches of Azilsartan solid dispersion were successfully 
compressed in to tablet by direct compression method. The 
tablets were evaluated for the various post-compression 
parameters and results are shown in table 3. Results showed 
that all post-compression parameters were found to be within 
acceptable limit with very good disintegration time and drug 
content. 
Tamboli et al. 
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Drug content (%) 
ASD-1 4.2±0.32 3.50±0.04 0.58±0.06 Passes 1.45±0.05 95.48±1.06 
ASD-2 3.5±0.24 3.49±0.02 0.52±0.05 Passes 0.78±0.02 98.97±0.25 
ASD-3 4.01±0.35 3.51±0.01 0.52±0.06 Passes 1.25±0.05 97.02±1.29 
ASD-4 3.8±0.58 3.53±0.02 0.60±0.04 Passes 1.5±0.08 96.98±1.02 
ASD-5 4.2±0.22 3.50±0.04 0.62±0.05 Passes 0.9±0.03 97.21±1.8 
ASD-6 3.6±0.27 3.52±0.03 0.57±0.06 Passes 1.27±0.08 98.25±2.1 
ASD-7 3.8±0.29 3.54±0.02 0.62±0.08 Passes 1.30±0.05 96.78±1.18 
ASD-8 4.2±0.35 3.51±0.05 0.65±0.07 Passes 0.75±0.03 97.29±1.8 
ASD-9 3.8±0.33 3.50±0.06 0.52±0.03 Passes 1.20±0.09 97.36±2.8 
All value represents mean±SD (n=3) 
 
In vitro dissolution study 
The results of in vitro dissolution study are shown in fig. 3. It showed 
that % drug releases of all batches within 30 min are enhanced as 
compared to plain Azilsartan. Results also indicated that, as the 
concentration of soluplus increases, drug release also increases. 
Batch ASD-2 containing 40 mg Azilsartan and 80 mg of Soluplus 
showed maximum drug release i.e. 99.82 % within 30 min. 
  
 
Fig. 3: Cumulative % drug release of Azilsartan Solid Dispersion tablets compared with plain azilsartan (All value represents mean±SD (n=3)) 
 
 
Fig. 4: FTIR spectrum of A: Azilsartan, B: Soluplus, C: Formulation ASD-2 
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From the results of solubility of solid dispersion and % drug 
dissolution after 30 min formulation of batch ASD-2 was 
considered as a satisfactory formulation and used for further 
evaluation [27]. 
Fourier transform infrared spectroscopy (FTIR) study 
Results of the FTIR study of Azilsartan, Soluplus and formulation 
ASD-2 are shown in fig. 4. Results indicate that all characteristic 
peaks of Azilsartan have retained in the FTIR spectra of formulation 
ASD-2. The deformation of characteristic peaks of azilsartan in 
formulation may be due to the formation of the amorphous state of 
Azilsartan. Hence results indicated no Imperative indication of 
chemical interaction between Azilsartan and 
Soluplus, which confirms the stability of Azilsartan in solid 
dispersion [28]. 
Differential scanning calorimetry (DSC) 
Results of DSC study of Azilsartan, Soluplus and formulation ASD-2 
are shown in fig. 5. It shows a sharp endothermic peak of Azilsartan 
at 208.52 °C. The formulation ASD-2 exhibit retained small 
endothermic peak of azilsartan at 214.73 and it may be due to 
molecular dispersion of Azilsartan in Soluplus. 
  
 
Fig. 5: DSC thermogram of A: Azilsartan, B: Soluplus, C: Formulation ASD-2 
 
X-ray diffraction studies (XRD) 
The powder X-ray diffractogram of Azilsartan, Soluplus and 
formulation ASD-2 are shown in fig. 6. The powder X-ray 
diffractogram of pure Azilsartan showed numerous distinctive peaks 
at that indicated a high crystallinity. The height of the characteristic 
peaks of azilsartan was remarkably reduced in case of diffractogram 
of formulation ASD-2 at low concentrations may have converted to a 
metastable amorphous form or may have dissolved in the matrix 
system [29]. 
Tamboli et al. 




Fig. 6: XRD of A: Azilsartan, B: Soluplus, C: Formulation ASD-2 
 
In vivo absorption study of azilsartan solid dispersion tablet 
The mean plasma concentration-time curves for pure Azilsartan and 
Formulation ASD-2 after oral administration to albino rats are 
shown in fig. 7. The Tmax and Cmax were obtained directly from the 
curves. It was indicated that Cmax was 31.59±3.95 µg/ml for pure 
Azilsartan and 58.93±3.63 µg/ml for Formulation ASD-2 
respectively, while the Tmax
  
 was 1 hour. AUC values for pure 
Azilsartan and Formulation ASD-2 were found 89.1 and 238.6 µg 
h/ml respectively. There are 2.67 fold increases in AUC. The relative 
bioavailability of immediate-release solid dispersion tablet 
compared with pure Azilsartan was 267.11%. 
 
Fig. 7: Plasma concentration-time profile of ASD2 and Azilsartan (All value represents mean±SD (n=3)) 
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Table 4: Stability study of ASD2 formulation 
Formulation Sampling time 
0 mo 1 mo 2 mo 3 mo 
% Drug released after 30 min 99.82±1.36 99.56±1.78 98.96±1.63 98.82±3.17 
Drug content (%) 98.97±0.25 98.85±1.02 98.65±1.15 98.56±0.85 
All value represents mean±SD (n=3) 
 
Accelerated stability study 
The stability data of formulation ASD2 is summarized in tables 4. 
After accelerated stability study, there were no significant changes 
in drug content and % Drug released after 30 min. Hence this 
formulation was found to be stable. 
CONCLUSION 
In the present study oral bioavailability of poorly water-soluble drug 
was enhanced using solid dispersion as a formulation strategy. The 
effect of different process parameters was studied using 32
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